{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T14:34:11Z","timestamp":1792852451861,"version":"4.5.0"},"reference-count":225,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T00:00:00Z","timestamp":1632355200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.apsb.2021.09.019","type":"journal-article","created":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T10:35:19Z","timestamp":1632738919000},"page":"558-580","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":627,"title":["Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma"],"prefix":"10.1016","volume":"12","author":[{"given":"Danyu","family":"Du","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyao","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengtao","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiping","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9712-6771","authenticated-orcid":false,"given":"Jing","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2021.09.019_bib1","first-page":"115","article-title":"Cancer statistics in China, 2015","volume":"66","author":"Chen","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.apsb.2021.09.019_bib2","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","article-title":"Hepatocellular carcinoma","volume":"391","author":"Forner","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.apsb.2021.09.019_bib3","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1056\/NEJMra1713263","article-title":"Hepatocellular carcinoma","volume":"380","author":"Villanueva","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2021.09.019_bib4","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1001\/jama.2010.1672","article-title":"Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial","volume":"304","author":"Abou-Alfa","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.apsb.2021.09.019_bib5","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1200\/JCO.2012.44.5643","article-title":"Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil\/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia","volume":"31","author":"Qin","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.apsb.2021.09.019_bib6","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2021.09.019_bib7","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.apsb.2021.09.019_bib8","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.apsb.2021.09.019_bib9","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in patients with advanced and progressing hepatocellular carcinoma","volume":"379","author":"Abou-Alfa","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2021.09.019_bib10","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S1470-2045(15)00050-9","article-title":"Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial","volume":"16","author":"Zhu","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.apsb.2021.09.019_bib11","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ctrv.2019.05.004","article-title":"Management of adverse events associated with tyrosine kinase inhibitors: improving outcomes for patients with hepatocellular carcinoma","volume":"77","author":"Rimassa","year":"2019","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.apsb.2021.09.019_bib12","doi-asserted-by":"crossref","first-page":"345","DOI":"10.4254\/wjh.v5.i7.345","article-title":"Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma","volume":"5","author":"Zhai","year":"2013","journal-title":"World J Hepatol"},{"key":"10.1016\/j.apsb.2021.09.019_bib13","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2021.09.019_bib14","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.apsb.2021.09.019_bib15","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1002\/hep.30921","article-title":"hnRNPU\/TrkB defines a chromatin accessibility checkpoint for liver injury and nonalcoholic steatohepatitis pathogenesis","volume":"71","author":"Xiong","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.apsb.2021.09.019_bib16","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S2468-1253(16)30018-8","article-title":"Distinctive features of hepatocellular carcinoma in non-alcoholic fatty liver disease","volume":"1","author":"Degasperi","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.apsb.2021.09.019_bib17","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.cgh.2015.08.010","article-title":"Trends in the burden of nonalcoholic fatty liver disease in a United States Cohort of Veterans","volume":"14","author":"Kanwal","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.apsb.2021.09.019_bib18","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2011.12.061","article-title":"Epidemiology of viral hepatitis and hepatocellular carcinoma","volume":"142","author":"El-Serag","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.apsb.2021.09.019_bib19","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1053\/j.gastro.2004.09.020","article-title":"Alcohol and hepatocellular carcinoma","volume":"127","author":"Morgan","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.apsb.2021.09.019_bib20","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.molmed.2018.02.006","article-title":"Genomic profiling and metabolic homeostasis in primary liver cancers","volume":"24","author":"Gingold","year":"2018","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.apsb.2021.09.019_bib21","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cmet.2015.12.006","article-title":"The emerging hallmarks of cancer metabolism","volume":"23","author":"Pavlova","year":"2016","journal-title":"Cell Metab"},{"key":"10.1016\/j.apsb.2021.09.019_bib22","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/nrc.2016.77","article-title":"Reprogramming glucose metabolism in cancer: can it be exploited for cancer therapy?.","volume":"16","author":"Hay","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.apsb.2021.09.019_bib23","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1126\/science.1160809","article-title":"Understanding the Warburg effect: the metabolic requirements of cell proliferation","volume":"324","author":"Vander Heiden","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.apsb.2021.09.019_bib24","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1007\/s10620-014-3364-3","article-title":"Evidence for heightened hexokinase II immunoexpression in hepatocyte dysplasia and hepatocellular carcinoma","volume":"60","author":"Guzman","year":"2015","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.apsb.2021.09.019_bib25","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.semcancer.2005.04.009","article-title":"Pyruvate kinase type M2 and its role in tumor growth and spreading","volume":"15","author":"Mazurek","year":"2005","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.apsb.2021.09.019_bib26","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.gde.2009.01.002","article-title":"The molecular determinants of de novo nucleotide biosynthesis in cancer cells","volume":"19","author":"Tong","year":"2009","journal-title":"Curr Opin Genet Dev"},{"key":"10.1016\/j.apsb.2021.09.019_bib27","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.3390\/cancers12061668","article-title":"Glucose metabolism and oxidative stress in hepatocellular carcinoma: role and possible implications in novel therapeutic strategies","volume":"12","author":"Mossenta","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.apsb.2021.09.019_bib28","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/hep.29202","article-title":"Glyceraldehyde-3-phosphate dehydrogenase promotes liver tumorigenesis by modulating phosphoglycerate dehydrogenase","volume":"66","author":"Liu","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.apsb.2021.09.019_bib29","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.canlet.2019.09.010","article-title":"NRF2 SUMOylation promotes de novo serine synthesis and maintains HCC tumorigenesis","volume":"466","author":"Guo","year":"2019","journal-title":"Cancer Lett"},{"key":"10.1016\/j.apsb.2021.09.019_bib30","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/nrd4204","article-title":"PI3K and cancer: lessons, challenges and opportunities","volume":"13","author":"Fruman","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2021.09.019_bib31","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1038\/cdd.2009.137","article-title":"Novel roles for GAPDH in cell death and carcinogenesis","volume":"16","author":"Colell","year":"2009","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.apsb.2021.09.019_bib32","doi-asserted-by":"crossref","first-page":"4947","DOI":"10.2147\/CMAR.S202268","article-title":"Nuclear GAPDH is vital for hypoxia-induced hepatic stellate cell apoptosis and is indicative of aggressive hepatocellular carcinoma behavior","volume":"11","author":"Gong","year":"2019","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.apsb.2021.09.019_bib33","doi-asserted-by":"crossref","first-page":"23757","DOI":"10.1016\/S0021-9258(17)31580-6","article-title":"Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1","volume":"269","author":"Semenza","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2021.09.019_bib34","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nrn1408","article-title":"HIF1 and oxygen sensing in the brain","volume":"5","author":"Sharp","year":"2004","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.apsb.2021.09.019_bib35","doi-asserted-by":"crossref","first-page":"525","DOI":"10.3892\/ijo.2016.3814","article-title":"Fructose-bisphosphate aldolase A is a key regulator of hypoxic adaptation in colorectal cancer cells and involved in treatment resistance and poor prognosis","volume":"50","author":"Kawai","year":"2017","journal-title":"Int J Oncol"},{"key":"10.1016\/j.apsb.2021.09.019_bib36","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1080\/15548627.2017.1381804","article-title":"Regulation of glycolytic metabolism by autophagy in liver cancer involves selective autophagic degradation of HK2 (hexokinase 2)","volume":"14","author":"Jiao","year":"2018","journal-title":"Autophagy"},{"key":"10.1016\/j.apsb.2021.09.019_bib37","doi-asserted-by":"crossref","first-page":"846","DOI":"10.18632\/oncotarget.2749","article-title":"PKM2 promotes metastasis by recruiting myeloid-derived suppressor cells and indicates poor prognosis for hepatocellular carcinoma","volume":"6","author":"Liu","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.apsb.2021.09.019_bib38","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.cell.2011.03.054","article-title":"Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1","volume":"145","author":"Luo","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2021.09.019_bib39","first-page":"1535","article-title":"PKM2 knockdown induces autophagic cell death via AKT\/mTOR pathway in human prostate cancer cells","volume":"52","author":"Dey","year":"2019","journal-title":"Cell Physiol Biochem"},{"key":"10.1016\/j.apsb.2021.09.019_bib40","doi-asserted-by":"crossref","first-page":"5174","DOI":"10.1002\/cam4.3080","article-title":"Long noncoding RNA MSC-AS1 promotes hepatocellular carcinoma oncogenesis via inducing the expression of phosphoglycerate kinase 1","volume":"9","author":"Cao","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.apsb.2021.09.019_bib41","doi-asserted-by":"crossref","first-page":"18805","DOI":"10.1002\/jcb.29196","article-title":"MicroRNA-450b-3p inhibits cell growth by targeting phosphoglycerate kinase 1 in hepatocellular carcinoma","volume":"120","author":"Chen","year":"2019","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.apsb.2021.09.019_bib42","doi-asserted-by":"crossref","first-page":"108487","DOI":"10.1016\/j.celrep.2020.108487","article-title":"HCAR1\/MCT1 regulates tumor ferroptosis through the lactate-mediated AMPK\u2013SCD1 activity and its therapeutic implications","volume":"33","author":"Zhao","year":"2020","journal-title":"Cell Rep"},{"key":"10.1016\/j.apsb.2021.09.019_bib43","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/s41586-019-1678-1","article-title":"Metabolic regulation of gene expression by histone lactylation","volume":"574","author":"Zhang","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2021.09.019_bib44","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.3390\/molecules24101993","article-title":"Quercetin inhibits the proliferation of glycolysis-addicted HCC cells by reducing hexokinase 2 and Akt\u2013mTOR pathway","volume":"24","author":"Wu","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.apsb.2021.09.019_bib45","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1111\/jcmm.14971","article-title":"Novel mitochondrion-targeting copper(II) complex induces HK2 malfunction and inhibits glycolysis via Drp1-mediating mitophagy in HCC","volume":"24","author":"Li","year":"2020","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.apsb.2021.09.019_bib46","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.freeradbiomed.2012.05.006","article-title":"The pentose phosphate pathway: an antioxidant defense and a crossroad in tumor cell fate","volume":"53","author":"Riganti","year":"2012","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.apsb.2021.09.019_bib47","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1136\/gutjnl-2013-305302","article-title":"PTEN antagonises Tcl1\/hnRNPK-mediated G6PD pre-mRNA splicing which contributes to hepatocarcinogenesis","volume":"63","author":"Hong","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.apsb.2021.09.019_bib48","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s13046-019-1131-1","article-title":"Transketolase (TKT) activity and nuclear localization promote hepatocellular carcinoma in a metabolic and a non-metabolic manner","volume":"38","author":"Qin","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.apsb.2021.09.019_bib49","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1016\/j.febslet.2012.05.052","article-title":"Glycolytic cancer cells lacking 6-phosphogluconate dehydrogenase metabolize glucose to induce senescence","volume":"586","author":"Sukhatme","year":"2012","journal-title":"FEBS Lett"},{"key":"10.1016\/j.apsb.2021.09.019_bib50","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1093\/abbs\/gmy009","article-title":"Elevated G6PD expression contributes to migration and invasion of hepatocellular carcinoma cells by inducing epithelial\u2013mesenchymal transition","volume":"50","author":"Lu","year":"2018","journal-title":"Acta Biochim Biophys Sin"},{"key":"10.1016\/j.apsb.2021.09.019_bib51","doi-asserted-by":"crossref","first-page":"E725","DOI":"10.1073\/pnas.1508779113","article-title":"Transketolase counteracts oxidative stress to drive cancer development","volume":"113","author":"Xu","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2021.09.019_bib52","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/sj.bjc.6602962","article-title":"Expression of transketolase TKTL1 predicts colon and urothelial cancer patient survival: Warburg effect reinterpreted","volume":"94","author":"Langbein","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.apsb.2021.09.019_bib53","doi-asserted-by":"crossref","first-page":"802","DOI":"10.3389\/fendo.2018.00802","article-title":"Unraveling the regulation of hepatic gluconeogenesis","volume":"9","author":"Zhang","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.apsb.2021.09.019_bib54","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/s41556-020-0511-2","article-title":"FBP1 loss disrupts liver metabolism and promotes tumorigenesis through a hepatic stellate cell senescence secretome","volume":"22","author":"Li","year":"2020","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.apsb.2021.09.019_bib55","doi-asserted-by":"crossref","first-page":"611","DOI":"10.3389\/fonc.2018.00611","article-title":"PCK1 downregulation promotes TXNRD1 expression and hepatoma cell growth via the Nrf2\/Keap1 pathway","volume":"8","author":"Tuo","year":"2018","journal-title":"Front Oncol"},{"key":"10.1016\/j.apsb.2021.09.019_bib56","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1006819","article-title":"Downregulation of SIRT1 signaling underlies hepatic autophagy impairment in glycogen storage disease type Ia","volume":"13","author":"Cho","year":"2017","journal-title":"PLoS Genet"},{"key":"10.1016\/j.apsb.2021.09.019_bib57","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1007\/s10545-018-0192-1","article-title":"Sirtuin signaling controls mitochondrial function in glycogen storage disease type Ia","volume":"41","author":"Cho","year":"2018","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.apsb.2021.09.019_bib58","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.bbrc.2018.03.083","article-title":"Hepatic glucose-6-phosphatase-\u03b1 deficiency leads to metabolic reprogramming in glycogen storage disease type Ia","volume":"498","author":"Cho","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.apsb.2021.09.019_bib59","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.molcel.2015.09.025","article-title":"PEPCK coordinates the regulation of central carbon metabolism to promote cancer cell growth","volume":"60","author":"Montal","year":"2015","journal-title":"Mol Cell"},{"key":"10.1016\/j.apsb.2021.09.019_bib60","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1038\/s41388-017-0070-6","article-title":"Metabolic reprogramming by PCK1 promotes TCA cataplerosis, oxidative stress and apoptosis in liver cancer cells and suppresses hepatocellular carcinoma","volume":"37","author":"Liu","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.apsb.2021.09.019_bib61","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/s41586-020-2183-2","article-title":"The gluconeogenic enzyme PCK1 phosphorylates INSIG1\/2 for lipogenesis","volume":"580","author":"Xu","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2021.09.019_bib62","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nature24057","article-title":"Glucose feeds the TCA cycle via circulating lactate","volume":"551","author":"Hui","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2021.09.019_bib63","doi-asserted-by":"crossref","first-page":"30409","DOI":"10.1074\/jbc.R200006200","article-title":"The key role of anaplerosis and cataplerosis for citric acid cycle function","volume":"277","author":"Owen","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2021.09.019_bib64","doi-asserted-by":"crossref","first-page":"108124","DOI":"10.1016\/j.abb.2019.108124","article-title":"Differential contribution of pyruvate carboxylation to anaplerosis and cataplerosis during non-gluconeogenic and gluconeogenic conditions in HepG2 cells","volume":"676","author":"Wattanavanitchakorn","year":"2019","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.apsb.2021.09.019_bib65","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3727\/096504018X15180451872087","article-title":"Overexpression of pyruvate dehydrogenase E1\u03b1 subunit inhibits Warburg effect and induces cell apoptosis through mitochondria-mediated pathway in hepatocellular carcinoma","volume":"27","author":"Sun","year":"2019","journal-title":"Oncol Res"},{"key":"10.1016\/j.apsb.2021.09.019_bib66","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1159\/000438593","article-title":"Isocitrate dehydrogenase 2 suppresses the invasion of hepatocellular carcinoma cells via matrix metalloproteinase 9","volume":"37","author":"Tian","year":"2015","journal-title":"Cell Physiol Biochem"},{"key":"10.1016\/j.apsb.2021.09.019_bib67","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1007\/s12032-014-0278-z","article-title":"Genetic variations in IDH gene as prognosis predictors in TACE-treated hepatocellular carcinoma patients","volume":"31","author":"Zhang","year":"2014","journal-title":"Med Oncol"},{"key":"10.1016\/j.apsb.2021.09.019_bib68","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1097\/DAD.0000000000000451","article-title":"Expression of malic enzymes in sebaceous lesions","volume":"38","author":"Su","year":"2016","journal-title":"Am J Dermatopath"},{"key":"10.1016\/j.apsb.2021.09.019_bib69","doi-asserted-by":"crossref","first-page":"6211","DOI":"10.1007\/s13277-015-3306-5","article-title":"Malic enzyme 1 induces epithelial\u2013mesenchymal transition and indicates poor prognosis in hepatocellular carcinoma","volume":"36","author":"Wen","year":"2015","journal-title":"Tumour Biol"},{"key":"10.1016\/j.apsb.2021.09.019_bib70","doi-asserted-by":"crossref","first-page":"101685","DOI":"10.1016\/j.redox.2020.101685","article-title":"Cytosolic ME1 integrated with mitochondrial IDH2 supports tumor growth and metastasis","volume":"36","author":"Shao","year":"2020","journal-title":"Redox Biol"},{"key":"10.1016\/j.apsb.2021.09.019_bib71","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.cell.2018.09.053","article-title":"Obesity drives STAT-1-dependent NASH and STAT-3-dependent HCC","volume":"175","author":"Grohmann","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2021.09.019_bib72","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2217\/hep-2016-0012","article-title":"Dysregulated fatty acid metabolism in hepatocellular carcinoma","volume":"3","author":"Wang","year":"2016","journal-title":"Hepat Oncol"},{"key":"10.1016\/j.apsb.2021.09.019_bib73","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.molcel.2019.09.008","article-title":"Even cancer cells watch their cholesterol!.","volume":"76","author":"Riscal","year":"2019","journal-title":"Mol Cell"},{"key":"10.1016\/j.apsb.2021.09.019_bib74","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.trecan.2020.03.001","article-title":"Drilling for oil: tumor-surrounding adipocytes fueling cancer","volume":"6","author":"Attane","year":"2020","journal-title":"Trends Cancer"},{"key":"10.1016\/j.apsb.2021.09.019_bib75","doi-asserted-by":"crossref","first-page":"14752","DOI":"10.1038\/srep14752","article-title":"Elevated free fatty acid uptake via CD36 promotes epithelial\u2013mesenchymal transition in hepatocellular carcinoma","volume":"5","author":"Nath","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.apsb.2021.09.019_bib76","doi-asserted-by":"crossref","first-page":"18229","DOI":"10.18632\/oncotarget.7571","article-title":"Liver fatty acid-binding protein (l-FABP) promotes cellular angiogenesis and migration in hepatocellular carcinoma","volume":"7","author":"Ku","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.apsb.2021.09.019_bib77","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/cam4.1020","article-title":"Fatty acid-binding protein 5 function in hepatocellular carcinoma through induction of epithelial\u2013mesenchymal transition","volume":"6","author":"Ohata","year":"2017","journal-title":"Cancer Med"},{"key":"10.1016\/j.apsb.2021.09.019_bib78","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s42003-020-01367-5","article-title":"Fatty-acid-induced FABP5\/HIF-1 reprograms lipid metabolism and enhances the proliferation of liver cancer cells","volume":"3","author":"Seo","year":"2020","journal-title":"Commun Biol"},{"key":"10.1016\/j.apsb.2021.09.019_bib79","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.3892\/or.2012.1922","article-title":"Fatty acid-binding protein 5 promotes cell proliferation and invasion in human intrahepatic cholangiocarcinoma","volume":"28","author":"Jeong","year":"2012","journal-title":"Oncol Rep"},{"key":"10.1016\/j.apsb.2021.09.019_bib80","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s00109-002-0384-9","article-title":"Lipoprotein lipase: structure, function, regulation, and role in disease","volume":"80","author":"Mead","year":"2002","journal-title":"J Mol Med (Berl)"},{"key":"10.1016\/j.apsb.2021.09.019_bib81","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/s41418-019-0453-z","article-title":"Tumor suppressor ZHX2 inhibits NAFLD-HCC progression via blocking LPL-mediated lipid uptake","volume":"27","author":"Wu","year":"2020","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.apsb.2021.09.019_bib82","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.canlet.2019.12.010","article-title":"ATP citrate lyase: a central metabolic enzyme in cancer","volume":"471","author":"Icard","year":"2020","journal-title":"Cancer Lett"},{"key":"10.1016\/j.apsb.2021.09.019_bib83","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1038\/nm.3372","article-title":"Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin","volume":"19","author":"Fullerton","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.apsb.2021.09.019_bib84","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.cmet.2018.08.020","article-title":"Inhibition of acetyl-CoA carboxylase by phosphorylation or the inhibitor ND-654 suppresses lipogenesis and hepatocellular carcinoma","volume":"29","author":"Lally","year":"2019","journal-title":"Cell Metab"},{"key":"10.1016\/j.apsb.2021.09.019_bib85","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.3389\/fonc.2019.01412","article-title":"Pathogenetic, prognostic, and therapeutic role of fatty acid synthase in human hepatocellular carcinoma","volume":"9","author":"Che","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.apsb.2021.09.019_bib86","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/00041433-200306000-00005","article-title":"Recent insights into stearoyl-CoA desaturase-1","volume":"14","author":"Ntambi","year":"2003","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.apsb.2021.09.019_bib87","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1016\/j.celrep.2015.05.025","article-title":"Hepatic SirT1-dependent gain of function of stearoyl-CoA desaturase-1 conveys dysmetabolic and tumor progression functions","volume":"11","author":"Qiang","year":"2015","journal-title":"Cell Rep"},{"key":"10.1016\/j.apsb.2021.09.019_bib88","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1053\/j.gastro.2017.01.021","article-title":"Stearoyl-CoA desaturase promotes liver fibrosis and tumor development in mice via a Wnt positive-signaling loop by stabilization of low-density lipoprotein-receptor-related proteins 5 and 6","volume":"152","author":"Lai","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.apsb.2021.09.019_bib89","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1002\/hep.30696","article-title":"Pharmacologic inhibition of epidermal growth factor receptor suppresses nonalcoholic fatty liver disease in a murine fast-food diet model","volume":"70","author":"Bhushan","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.apsb.2021.09.019_bib90","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.canlet.2014.12.036","article-title":"SCD1 negatively regulates autophagy-induced cell death in human hepatocellular carcinoma through inactivation of the AMPK signaling pathway","volume":"358","author":"Huang","year":"2015","journal-title":"Cancer Lett"},{"key":"10.1016\/j.apsb.2021.09.019_bib91","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.jhep.2017.06.015","article-title":"Stearoyl-CoA desaturase regulates sorafenib resistance via modulation of ER stress-induced differentiation","volume":"67","author":"Ma","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.apsb.2021.09.019_bib92","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/s41389-020-0226-z","article-title":"ACSL4 promotes hepatocellular carcinoma progression via c-Myc stability mediated by ERK\/FBW7\/c-Myc axis","volume":"9","author":"Chen","year":"2020","journal-title":"Oncogenesis"},{"key":"10.1016\/j.apsb.2021.09.019_bib93","doi-asserted-by":"crossref","first-page":"7124","DOI":"10.3390\/ijms15057124","article-title":"SREBP-1 has a prognostic role and contributes to invasion and metastasis in human hepatocellular carcinoma","volume":"15","author":"Li","year":"2014","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2021.09.019_bib94","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.bbrc.2005.04.147","article-title":"Selection of DNA aptamers against rat liver X receptors","volume":"332","author":"Surugiu-W\u00e4rnmark","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.apsb.2021.09.019_bib95","doi-asserted-by":"crossref","first-page":"G598","DOI":"10.1152\/ajpgi.00061.2018","article-title":"TO901317 inhibits the development of hepatocellular carcinoma by LXR\u03b1\/Glut1 decreasing glycometabolism","volume":"316","author":"Xiong","year":"2019","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.apsb.2021.09.019_bib96","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1007\/s10620-014-3289-x","article-title":"Expression of liver X receptor correlates with intrahepatic inflammation and fibrosis in patients with nonalcoholic fatty liver disease","volume":"59","author":"Ahn","year":"2014","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.apsb.2021.09.019_bib97","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/jgh.15239","article-title":"Oxidative stress and liver X receptor agonist induce hepatocellular carcinoma in non-alcoholic steatohepatitis model","volume":"36","author":"Shimizu","year":"2020","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.apsb.2021.09.019_bib98","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/mc.22967","article-title":"Metabolic profiling analysis upon acylcarnitines in tissues of hepatocellular carcinoma revealed the inhibited carnitine shuttle system caused by the downregulated carnitine palmitoyltransferase 2","volume":"58","author":"Lu","year":"2019","journal-title":"Mol Carcinog"},{"key":"10.1016\/j.apsb.2021.09.019_bib99","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1002\/hep.28415","article-title":"Acetyl-coenzyme A carboxylase alpha promotion of glucose-mediated fatty acid synthesis enhances survival of hepatocellular carcinoma in mice and patients","volume":"63","author":"Wang","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.apsb.2021.09.019_bib100","article-title":"HIF-1 suppresses lipid catabolism to promote cancer progression","volume":"2","author":"Zhang","year":"2015","journal-title":"Mol Cell Oncol"},{"key":"10.1016\/j.apsb.2021.09.019_bib101","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1016\/j.celrep.2014.08.028","article-title":"HIF-1-mediated suppression of acyl-CoA dehydrogenases and fatty acid oxidation is critical for cancer progression","volume":"8","author":"Huang","year":"2014","journal-title":"Cell Rep"},{"key":"10.1016\/j.apsb.2021.09.019_bib102","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1590\/2359-3997000000067","article-title":"Lipolysis and lipases in white adipose tissue\u2014an update","volume":"59","author":"Bolsoni-Lopes","year":"2015","journal-title":"Arch Endocrinol Metab"},{"key":"10.1016\/j.apsb.2021.09.019_bib103","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s13045-016-0361-3","article-title":"Monoacylglycerol lipase promotes progression of hepatocellular carcinoma via NF-\u03baB-mediated epithelial\u2013mesenchymal transition","volume":"9","author":"Zhu","year":"2016","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.apsb.2021.09.019_bib104","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s12943-018-0838-5","article-title":"Long non-coding RNA NEAT1-modulated abnormal lipolysis via ATGL drives hepatocellular carcinoma proliferation","volume":"17","author":"Liu","year":"2018","journal-title":"Mol Cancer"},{"key":"10.1016\/j.apsb.2021.09.019_bib105","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1136\/gutjnl-2018-317581","article-title":"Cholesterol biosynthesis supports the growth of hepatocarcinoma lesions depleted of fatty acid synthase in mice and humans","volume":"69","author":"Che","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.apsb.2021.09.019_bib106","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/nrc.2016.76","article-title":"The interplay between cell signalling and the mevalonate pathway in cancer","volume":"16","author":"Mullen","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.apsb.2021.09.019_bib107","doi-asserted-by":"crossref","first-page":"5246","DOI":"10.1158\/0008-5472.CAN-07-6161","article-title":"Mitochondrial cholesterol contributes to chemotherapy resistance in hepatocellular carcinoma","volume":"68","author":"Montero","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2021.09.019_bib108","first-page":"649","article-title":"Peroxisome proliferator-activated receptors: nuclear control of metabolism","volume":"20","author":"Desvergne","year":"1999","journal-title":"Endocr Rev"},{"key":"10.1016\/j.apsb.2021.09.019_bib109","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/hep.30530","article-title":"Keratin 23 is a peroxisome proliferator-activated receptor alpha-dependent, MYC-amplified oncogene that promotes hepatocyte proliferation","volume":"70","author":"Kim","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.apsb.2021.09.019_bib110","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.3390\/ijms20174274","article-title":"Molecular functionality of cytochrome P450 4 (CYP4) genetic polymorphisms and their clinical implications","volume":"20","author":"Jarrar","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2021.09.019_bib111","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1016\/j.bcp.2008.03.004","article-title":"Cytochrome P450 omega hydroxylase (CYP4) function in fatty acid metabolism and metabolic diseases","volume":"75","author":"Hardwick","year":"2008","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.apsb.2021.09.019_bib112","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1158\/0008-5472.CAN-03-0849","article-title":"Identification of a novel mammary-restricted cytochrome P450, CYP4Z1, with overexpression in breast carcinoma","volume":"64","author":"Rieger","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2021.09.019_bib113","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.taap.2012.07.019","article-title":"Increased expression of CYP4Z1 promotes tumor angiogenesis and growth in human breast cancer","volume":"264","author":"Yu","year":"2012","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.apsb.2021.09.019_bib114","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.bbrc.2014.09.112","article-title":"Pseudogene CYP4Z2P 3\u2032UTR promotes angiogenesis in breast cancer","volume":"453","author":"Zheng","year":"2014","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.apsb.2021.09.019_bib115","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13045-019-0697-6","article-title":"Transcriptional factor six2 promotes the competitive endogenous RNA network between CYP4Z1 and pseudogene CYP4Z2P responsible for maintaining the stemness of breast cancer cells","volume":"12","author":"Zheng","year":"2019","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.apsb.2021.09.019_bib116","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.15252\/embj.201696151","article-title":"Cancer cell metabolism: the essential role of the nonessential amino acid, glutamine","volume":"36","author":"Zhang","year":"2017","journal-title":"EMBO J"},{"key":"10.1016\/j.apsb.2021.09.019_bib117","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1016\/j.bbamcr.2015.12.017","article-title":"Glutamine transporters in mammalian cells and their functions in physiology and cancer","volume":"1863","author":"Bhutia","year":"2016","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.apsb.2021.09.019_bib118","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1146\/annurev-bioeng-071516-044546","article-title":"Glutaminolysis: a hallmark of cancer metabolism","volume":"19","author":"Yang","year":"2017","journal-title":"Annu Rev Biomed Eng"},{"key":"10.1016\/j.apsb.2021.09.019_bib119","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yexcr.2019.04.005","article-title":"GLS1 promotes proliferation in hepatocellular carcinoma cells via AKT\/GSK3beta\/Cyclin D1 pathway","volume":"381","author":"Xi","year":"2019","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.apsb.2021.09.019_bib120","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ebiom.2018.11.063","article-title":"Targeting glutaminase 1 attenuates stemness properties in hepatocellular carcinoma by increasing reactive oxygen species and suppressing Wnt\/beta-catenin pathway","volume":"39","author":"Li","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.apsb.2021.09.019_bib121","doi-asserted-by":"crossref","first-page":"7461","DOI":"10.1073\/pnas.1002459107","article-title":"Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species","volume":"107","author":"Suzuki","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2021.09.019_bib122","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jcmgh.2019.12.006","article-title":"Increased glutaminolysis marks active scarring in nonalcoholic steatohepatitis progression","volume":"10","author":"Du","year":"2020","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1016\/j.apsb.2021.09.019_bib123","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jmcb\/mjy052","article-title":"The SLC transporter in nutrient and metabolic sensing, regulation, and drug development","volume":"11","author":"Zhang","year":"2019","journal-title":"J Mol Cell Biol"},{"key":"10.1016\/j.apsb.2021.09.019_bib124","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3389\/fcell.2018.00096","article-title":"The human SLC1A5 (ASCT2) amino acid transporter: from function to structure and role in cell biology","volume":"6","author":"Scalise","year":"2018","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.apsb.2021.09.019_bib125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0168907","article-title":"GLUT1 and ASCT2 as predictors for prognosis of hepatocellular carcinoma","volume":"11","author":"Sun","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.apsb.2021.09.019_bib126","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1042\/BJ20040487","article-title":"Glutamine availability up-regulates expression of the amino acid transporter protein ASCT2 in HepG2 cells and stimulates the ASCT2 promoter","volume":"382","author":"Bungard","year":"2004","journal-title":"Biochem J"},{"key":"10.1016\/j.apsb.2021.09.019_bib127","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3389\/fchem.2018.00243","article-title":"The Human SLC7A5 (LAT1): the intriguing histidine\/large neutral amino acid transporter and its relevance to human health","volume":"6","author":"Scalise","year":"2018","journal-title":"Front Chem"},{"key":"10.1016\/j.apsb.2021.09.019_bib128","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/jso.1165","article-title":"Expression of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (4F2hc) in liver tumor lesions of rat models","volume":"78","author":"Ohkame","year":"2001","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.apsb.2021.09.019_bib129","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/hep.28223","article-title":"Yes-associated protein 1 and transcriptional coactivator with PDZ-binding motif activate the mammalian target of rapamycin complex 1 pathway by regulating amino acid transporters in hepatocellular carcinoma","volume":"63","author":"Park","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.apsb.2021.09.019_bib130","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/j.cellsig.2014.04.002","article-title":"Downregulation of LAT1 expression suppresses cholangiocarcinoma cell invasion and migration","volume":"26","author":"Janpipatkul","year":"2014","journal-title":"Cell Signal"},{"key":"10.1016\/j.apsb.2021.09.019_bib131","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1007\/s13277-013-0861-5","article-title":"The impact of L-type amino acid transporter 1 (LAT1) in human hepatocellular carcinoma","volume":"34","author":"Li","year":"2013","journal-title":"Tumour Biol"},{"key":"10.1016\/j.apsb.2021.09.019_bib132","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41586-019-1011-z","article-title":"Structure of the human LAT1-4F2hc heteromeric amino acid transporter complex","volume":"568","author":"Yan","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2021.09.019_bib133","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.amjms.2020.08.010","article-title":"LncRNA TMPO-AS1 aggravates the development of hepatocellular carcinoma via miR-429\/GOT1 axis","volume":"360","author":"Liu","year":"2020","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.apsb.2021.09.019_bib134","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.apsb.2019.03.002","article-title":"Targeting the untargetable KRAS in cancer therapy","volume":"9","author":"Liu","year":"2019","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2021.09.019_bib135","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ymgme.2010.08.002","article-title":"Genetic, structural and biochemical basis of carbamoyl phosphate synthetase 1 deficiency","volume":"101","author":"Martinez","year":"2010","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.apsb.2021.09.019_bib136","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.cell.2017.05.046","article-title":"Comprehensive and integrative genomic characterization of hepatocellular carcinoma","volume":"169","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2021.09.019_bib137","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.gene.2016.07.031","article-title":"Studies on the biological functions of CPS1 in AFB1 induced hepatocarcinogenesis","volume":"591","author":"Yang","year":"2016","journal-title":"Gene"},{"key":"10.1016\/j.apsb.2021.09.019_bib138","doi-asserted-by":"crossref","first-page":"251","DOI":"10.4143\/crt.2013.45.4.251","article-title":"Targeting arginine-dependent cancers with arginine-degrading enzymes: opportunities and challenges","volume":"45","author":"Phillips","year":"2013","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.apsb.2021.09.019_bib139","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/abbs\/gmz005","article-title":"Argininosuccinate synthase 1 suppresses cancer cell invasion by inhibiting STAT3 pathway in hepatocellular carcinoma","volume":"51","author":"Tao","year":"2019","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"key":"10.1016\/j.apsb.2021.09.019_bib140","doi-asserted-by":"crossref","first-page":"2109865","DOI":"10.1155\/2018\/2109865","article-title":"The oncogenic role of ARG1 in progression and metastasis of hepatocellular carcinoma","volume":"2018","author":"You","year":"2018","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.apsb.2021.09.019_bib141","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27392","article-title":"Acquired ornithine transcarbamylase deficiency in pediatric and adolescent patients with fibrolamellar hepatocellular carcinoma","volume":"65","author":"Bartlett","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.apsb.2021.09.019_bib142","first-page":"5030","article-title":"Ornithine transcarbamylase downregulation is associated with poor prognosis in hepatocellular carcinoma","volume":"17","author":"He","year":"2019","journal-title":"Oncol Lett"},{"key":"10.1016\/j.apsb.2021.09.019_bib143","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.3349\/ymj.2018.59.10.1143","article-title":"Cancer metabolism as a mechanism of treatment resistance and potential therapeutic target in hepatocellular carcinoma","volume":"59","author":"Lee","year":"2018","journal-title":"Yonsei Med J"},{"key":"10.1016\/j.apsb.2021.09.019_bib144","doi-asserted-by":"crossref","first-page":"800","DOI":"10.3892\/ol.2016.5510","article-title":"2-Deoxyglucose and sorafenib synergistically suppress the proliferation and motility of hepatocellular carcinoma cells","volume":"13","author":"Tomizawa","year":"2017","journal-title":"Oncol Lett"},{"key":"10.1016\/j.apsb.2021.09.019_bib145","doi-asserted-by":"crossref","first-page":"5359","DOI":"10.2147\/OTT.S212465","article-title":"The combination of the glycolysis inhibitor 2-DG and sorafenib can be effective against sorafenib-tolerant persister cancer cells","volume":"12","author":"Wang","year":"2019","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.apsb.2021.09.019_bib146","doi-asserted-by":"crossref","first-page":"113988","DOI":"10.1016\/j.bcp.2020.113988","article-title":"3-Bromopyruvate regulates the status of glycolysis and BCNU sensitivity in human hepatocellular carcinoma cells","volume":"177","author":"Sun","year":"2020","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.apsb.2021.09.019_bib147","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1042\/BJ20080805","article-title":"Inhibition of energy-producing pathways of HepG2 cells by 3-bromopyruvate","volume":"417","author":"Pereira da Silva","year":"2009","journal-title":"Biochem J"},{"key":"10.1016\/j.apsb.2021.09.019_bib148","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.cbi.2017.04.015","article-title":"Antitumor and chemosensitizing action of 3-bromopyruvate: implication of deregulated metabolism","volume":"270","author":"Yadav","year":"2017","journal-title":"Chem Biol Interact"},{"key":"10.1016\/j.apsb.2021.09.019_bib149","first-page":"4909","article-title":"Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is pyruvylated during 3-bromopyruvate mediated cancer cell death","volume":"29","author":"Ganapathy-Kanniappan","year":"2009","journal-title":"Anticancer Res"},{"key":"10.1016\/j.apsb.2021.09.019_bib150","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.cmet.2017.08.017","article-title":"A predictive model for selective targeting of the Warburg effect through GAPDH inhibition with a natural product","volume":"26","author":"Liberti","year":"2017","journal-title":"Cell Metab"},{"key":"10.1016\/j.apsb.2021.09.019_bib151","first-page":"2280","article-title":"PGK1-mediated cancer progression and drug resistance","volume":"9","author":"He","year":"2019","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.apsb.2021.09.019_bib152","doi-asserted-by":"crossref","first-page":"114343","DOI":"10.1016\/j.bcp.2020.114343","article-title":"Identification of a novel non-ATP-competitive protein kinase inhibitor of PGK1 from marine nature products","volume":"183","author":"Wang","year":"2020","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.apsb.2021.09.019_bib153","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/s41401-020-0465-8","article-title":"Pharmacologically inhibiting phosphoglycerate kinase 1 for glioma with NG52","volume":"42","author":"Wang","year":"2020","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.apsb.2021.09.019_bib154","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.ccr.2012.09.020","article-title":"Phosphoglycerate mutase 1 coordinates glycolysis and biosynthesis to promote tumor growth","volume":"22","author":"Hitosugi","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.apsb.2021.09.019_bib155","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13046-017-0514-4","article-title":"Chrysin inhibited tumor glycolysis and induced apoptosis in hepatocellular carcinoma by targeting hexokinase-2","volume":"36","author":"Xu","year":"2017","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.apsb.2021.09.019_bib156","doi-asserted-by":"crossref","first-page":"45965","DOI":"10.18632\/oncotarget.17469","article-title":"Methyl jasmonate leads to necrosis and apoptosis in hepatocellular carcinoma cells via inhibition of glycolysis and represses tumor growth in mice","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.apsb.2021.09.019_bib157","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12967-017-1223-7","article-title":"Shikonin-induced necroptosis is enhanced by the inhibition of autophagy in non-small cell lung cancer cells","volume":"15","author":"Kim","year":"2017","journal-title":"J Transl Med"},{"key":"10.1016\/j.apsb.2021.09.019_bib158","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.lfs.2018.05.012","article-title":"Shikonin enhances sensitization of gefitinib against wild-type EGFR non-small cell lung cancer via inhibition PKM2\/STAT3\/cyclin D1 signal pathway","volume":"204","author":"Tang","year":"2018","journal-title":"Life Sci"},{"key":"10.1016\/j.apsb.2021.09.019_bib159","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2147\/JHC.S237614","article-title":"Experimental study of hepatocellular carcinoma treatment by shikonin through regulating PKM2","volume":"7","author":"Liu","year":"2020","journal-title":"J Hepatocell Carcino"},{"key":"10.1016\/j.apsb.2021.09.019_bib160","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1038\/bjc.2017.323","article-title":"Genistein suppresses aerobic glycolysis and induces hepatocellular carcinoma cell death","volume":"117","author":"Li","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.apsb.2021.09.019_bib161","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1021\/acs.jproteome.8b00029","article-title":"Anti-cancer effects of emodin on HepG2 cells as revealed by 1H NMR based metabolic profiling","volume":"17","author":"Xing","year":"2018","journal-title":"J Proteome Res"},{"key":"10.1016\/j.apsb.2021.09.019_bib162","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.phymed.2018.09.003","article-title":"DT-13 inhibited the proliferation of colorectal cancer via glycolytic metabolism and AMPK\/mTOR signaling pathway","volume":"54","author":"Wei","year":"2019","journal-title":"Phytomedicine"},{"key":"10.1016\/j.apsb.2021.09.019_bib163","doi-asserted-by":"crossref","first-page":"43864","DOI":"10.1038\/srep43864","article-title":"Inhibiting histone deacetylases suppresses glucose metabolism and hepatocellular carcinoma growth by restoring FBP1 expression","volume":"7","author":"Yang","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.apsb.2021.09.019_bib164","article-title":"Suppression of gluconeogenic gene expression by LSD1-mediated histone demethylation","volume":"8","author":"Pan","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.apsb.2021.09.019_bib165","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/oncsis.2017.21","article-title":"MAGE\u2013TRIM28 complex promotes the Warburg effect and hepatocellular carcinoma progression by targeting FBP1 for degradation","volume":"6","author":"Jin","year":"2017","journal-title":"Oncogenesis"},{"key":"10.1016\/j.apsb.2021.09.019_bib166","doi-asserted-by":"crossref","first-page":"4408","DOI":"10.1021\/bi0618621","article-title":"trans-2-Phenylcyclopropylamine is a mechanism-based inactivator of the histone demethylase LSD1","volume":"46","author":"Schmidt Dawn","year":"2007","journal-title":"Biochemistry"},{"key":"10.1016\/j.apsb.2021.09.019_bib167","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13148-019-0675-4","article-title":"Epigenetics in cancer therapy and nanomedicine","volume":"11","author":"Roberti","year":"2019","journal-title":"Clin Epigenetics"},{"key":"10.1016\/j.apsb.2021.09.019_bib168","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s10637-010-9532-1","article-title":"An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma","volume":"30","author":"Kim","year":"2012","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.apsb.2021.09.019_bib169","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1038\/ncomms3508","article-title":"Switch of glycolysis to gluconeogenesis by dexamethasone for treatment of hepatocarcinoma","volume":"4","author":"Ma","year":"2013","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2021.09.019_bib170","doi-asserted-by":"crossref","first-page":"5615","DOI":"10.1021\/jm2005805","article-title":"The lipogenesis pathway as a cancer target","volume":"54","author":"Abramson","year":"2011","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2021.09.019_bib171","doi-asserted-by":"crossref","first-page":"3866","DOI":"10.1016\/j.bmc.2018.03.014","article-title":"Design, synthesis and biological evaluation of novel spiro-pentacylamides as acetyl-CoA carboxylase inhibitors","volume":"26","author":"Wei","year":"2018","journal-title":"Bioorgan Med Chem"},{"key":"10.1016\/j.apsb.2021.09.019_bib172","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1158\/1538-7445.AM2016-3781","article-title":"Combination therapy with a liver selective acetyl-CoA carboxylase inhibitor ND-654 and sorafenib improves efficacy in the treatment of cirrhotic rats with hepatocellular carcinoma","volume":"76","author":"Wei","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2021.09.019_bib173","first-page":"7330","article-title":"Fatty acid synthase inhibition triggers apoptosis during S phase in human cancer cells","volume":"63","author":"Zhou","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2021.09.019_bib174","doi-asserted-by":"crossref","first-page":"551","DOI":"10.2217\/fon.10.11","article-title":"Fatty acid synthase as a potential therapeutic target in cancer","volume":"6","author":"Flavin","year":"2010","journal-title":"Future Oncol"},{"key":"10.1016\/j.apsb.2021.09.019_bib175","doi-asserted-by":"crossref","first-page":"CT153","DOI":"10.1158\/1538-7445.AM2017-CT153","article-title":"Abstract CT153: first in human study of the first-in-class fatty acid synthase (FASN) inhibitor TVB-2640","volume":"77","author":"Falchook","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2021.09.019_bib176","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.1016\/S0168-8278(17)30460-9","article-title":"Establishing the foundation for a novel, first-in-class, fatty acid synthase inhibitor, TVB-2640, for the treatment of NASH","volume":"66","author":"Duke","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.apsb.2021.09.019_bib177","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1161\/ATVBAHA.113.302677","article-title":"Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol-lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus","volume":"34","author":"Gutierrez","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.apsb.2021.09.019_bib178","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","article-title":"Safety and efficacy of bempedoic acid to reduce LDL cholesterol","volume":"380","author":"Ray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2021.09.019_bib179","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ccr.2005.09.008","article-title":"ATP citrate lyase inhibition can suppress tumor cell growth","volume":"8","author":"Hatzivassiliou","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.apsb.2021.09.019_bib180","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.canlet.2014.03.015","article-title":"Inactivation of ATP citrate lyase by cucurbitacin B: a bioactive compound from cucumber, inhibits prostate cancer growth","volume":"349","author":"Gao","year":"2014","journal-title":"Cancer Lett"},{"key":"10.1016\/j.apsb.2021.09.019_bib181","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4062\/biomolther.2017.178","article-title":"Targeting glutamine metabolism for cancer treatment","volume":"26","author":"Choi","year":"2018","journal-title":"Biomol Ther (Seoul)"},{"key":"10.1016\/j.apsb.2021.09.019_bib182","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1021\/acs.jmedchem.8b01198","article-title":"Novel 1,3,4-selenadiazole-containing kidney-type glutaminase inhibitors showed improved cellular uptake and antitumor activity","volume":"62","author":"Chen","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2021.09.019_bib183","doi-asserted-by":"crossref","first-page":"10551","DOI":"10.1021\/jm301191p","article-title":"Design, synthesis, and pharmacological evaluation of bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide 3 (BPTES) analogs as glutaminase inhibitors","volume":"55","author":"Shukla","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2021.09.019_bib184","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1158\/1535-7163.MCT-13-0870","article-title":"Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer","volume":"13","author":"Gross","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.apsb.2021.09.019_bib185","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/nm.4464","article-title":"Pharmacological blockade of ASCT2-dependent glutamine transport leads to\u00a0antitumor efficacy in preclinical models","volume":"24","author":"Schulte","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.apsb.2021.09.019_bib186","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.56749","article-title":"A powerful drug combination strategy targeting glutamine addiction for the treatment of human liver cancer","volume":"9","author":"Jin","year":"2020","journal-title":"Elife"},{"key":"10.1016\/j.apsb.2021.09.019_bib187","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.phymed.2018.12.011","article-title":"Topotecan induces apoptosis via ASCT2 mediated oxidative stress in gastric cancer","volume":"57","author":"Wang","year":"2019","journal-title":"Phytomedicine"},{"key":"10.1016\/j.apsb.2021.09.019_bib188","doi-asserted-by":"crossref","first-page":"11751","DOI":"10.2147\/OTT.S235667","article-title":"Berberine inhibits growth of liver cancer cells by suppressing glutamine uptake","volume":"12","author":"Zhang","year":"2019","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.apsb.2021.09.019_bib189","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1007\/s40265-018-0978-3","article-title":"Ivosidenib: first global approval","volume":"78","author":"Dhillon","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.apsb.2021.09.019_bib190","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1021\/acs.jmedchem.9b01423","article-title":"Structure-based design and identification of FT-2102 (olutasidenib), a potent mutant-selective IDH1 inhibitor","volume":"63","author":"Caravella","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2021.09.019_bib191","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.ccell.2017.11.011","article-title":"mTORC2 promotes tumorigenesis via lipid synthesis","volume":"32","author":"Guri","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.apsb.2021.09.019_bib192","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1158\/1535-7163.MCT-07-0445","article-title":"A new mechanism of drug resistance in breast cancer cells: fatty acid synthase overexpression-mediated palmitate overproduction","volume":"7","author":"Liu","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.apsb.2021.09.019_bib193","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1093\/annonc\/mdi239","article-title":"Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2\/neu (erbB-2) oncogene","volume":"16","author":"Menendez","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.apsb.2021.09.019_bib194","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.pharmthera.2017.02.021","article-title":"Fatty acid synthase\u2014modern tumor cell biology insights into a classical oncology target","volume":"177","author":"Buckley","year":"2017","journal-title":"Pharmacol Therapeut"},{"key":"10.1016\/j.apsb.2021.09.019_bib195","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1080\/14728222.2017.1381087","article-title":"Fatty acid synthase (FASN) as a therapeutic target in breast cancer","volume":"21","author":"Menendez","year":"2017","journal-title":"Expert Opin Ther Tar"},{"key":"10.1016\/j.apsb.2021.09.019_bib196","doi-asserted-by":"crossref","first-page":"24787","DOI":"10.18632\/oncotarget.25361","article-title":"Preclinical evaluation of novel fatty acid synthase inhibitors in primary colorectal cancer cells and a patient-derived xenograft model of colorectal cancer","volume":"9","author":"Zaytseva","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.apsb.2021.09.019_bib197","doi-asserted-by":"crossref","first-page":"9498","DOI":"10.1073\/pnas.132128899","article-title":"C75 increases peripheral energy utilization and fatty acid oxidation in diet-induced obesity","volume":"99","author":"Thupari","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2021.09.019_bib198","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1159\/000156702","article-title":"Chemoembolization combined with pravastatin improves survival\u00a0in\u00a0patients with hepatocellular carcinoma","volume":"78","author":"Graf","year":"2008","journal-title":"Digestion"},{"key":"10.1016\/j.apsb.2021.09.019_bib199","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1007\/s10637-020-00924-3","article-title":"First-in-human phase I study of JPH203, an L-type amino acid transporter 1 inhibitor, in patients with advanced solid tumors","volume":"38","author":"Okano","year":"2020","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.apsb.2021.09.019_bib200","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1001\/jama.2017.17535","article-title":"Encouraging new uses for old drugs","volume":"318","author":"Sachs","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.apsb.2021.09.019_bib201","article-title":"New uses for old drugs","volume":"361","author":"Pantziarka","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.apsb.2021.09.019_bib202","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/s41467-017-02733-4","article-title":"Hexokinase-2 depletion inhibits glycolysis and induces oxidative phosphorylation in hepatocellular carcinoma and sensitizes to metformin","volume":"9","author":"DeWaal","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2021.09.019_bib203","doi-asserted-by":"crossref","first-page":"116966","DOI":"10.1016\/j.lfs.2019.116966","article-title":"Metformin attenuates hepatoma cell proliferation by decreasing glycolytic flux through the HIF-1alpha\/PFKFB3\/PFK1 pathway","volume":"239","author":"Hu","year":"2019","journal-title":"Life Sci"},{"key":"10.1016\/j.apsb.2021.09.019_bib204","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1002\/ijc.31193","article-title":"Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake","volume":"142","author":"Kaji","year":"2018","journal-title":"Int J Cancer"},{"key":"10.1016\/j.apsb.2021.09.019_bib205","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1038\/s41598-018-19658-7","article-title":"Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH","volume":"8","author":"Shiba","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.apsb.2021.09.019_bib206","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s12943-017-0701-0","article-title":"Metformin suppresses cancer initiation and progression in genetic mouse models of pancreatic cancer","volume":"16","author":"Chen","year":"2017","journal-title":"Mol Cancer"},{"key":"10.1016\/j.apsb.2021.09.019_bib207","doi-asserted-by":"crossref","first-page":"5666","DOI":"10.1038\/s41388-018-0360-7","article-title":"Metformin sensitizes endometrial cancer cells to chemotherapy through IDH1-induced Nrf2 expression via an epigenetic mechanism","volume":"37","author":"Bai","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.apsb.2021.09.019_bib208","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.cmet.2016.09.005","article-title":"Metformin targets central carbon metabolism and reveals mitochondrial requirements in human cancers","volume":"24","author":"Liu","year":"2016","journal-title":"Cell Metab"},{"key":"10.1016\/j.apsb.2021.09.019_bib209","doi-asserted-by":"crossref","first-page":"10804","DOI":"10.1158\/0008-5472.CAN-07-2310","article-title":"Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells","volume":"67","author":"Dowling","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2021.09.019_bib210","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1073\/pnas.0308061100","article-title":"The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress","volume":"101","author":"Shaw","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2021.09.019_bib211","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S0140-6736(13)62365-X","article-title":"Type 2 diabetes as a redox disease","volume":"383","author":"Watson","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.apsb.2021.09.019_bib212","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0136250","article-title":"Metformin induces apoptosis and downregulates pyruvate kinase M2 in breast cancer cells only when grown in nutrient-poor conditions","volume":"10","author":"Silvestri","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.apsb.2021.09.019_bib213","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13058-015-0598-8","article-title":"Metformin in breast cancer\u2014an evolving mystery","volume":"17","author":"Camacho","year":"2015","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.apsb.2021.09.019_bib214","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/liv.13280","article-title":"Metformin confers risk reduction for developing hepatocellular carcinoma recurrence after liver resection","volume":"37","author":"Chan","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.apsb.2021.09.019_bib215","doi-asserted-by":"crossref","first-page":"E4111","DOI":"10.1073\/pnas.1511698112","article-title":"Functional expression of sodium\u2013glucose transporters in cancer","volume":"112","author":"Scafoglio","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2021.09.019_bib216","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.2353\/ajpath.2009.080596","article-title":"GLUT1 expression is increased in hepatocellular carcinoma and promotes tumorigenesis","volume":"174","author":"Amann","year":"2009","journal-title":"Am J Pathol"},{"key":"10.1016\/j.apsb.2021.09.019_bib217","doi-asserted-by":"crossref","first-page":"58353","DOI":"10.18632\/oncotarget.16874","article-title":"Preventive effects of the sodium glucose cotransporter 2 inhibitor tofogliflozin on diethylnitrosamine-induced liver tumorigenesis in obese and diabetic mice","volume":"8","author":"Obara","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.apsb.2021.09.019_bib218","doi-asserted-by":"crossref","first-page":"G887","DOI":"10.1152\/ajpgi.00068.2016","article-title":"Intestinal SGLT1 in metabolic health and disease","volume":"310","author":"Lehmann","year":"2016","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.apsb.2021.09.019_bib219","doi-asserted-by":"crossref","first-page":"10089","DOI":"10.1096\/fj.201802619RR","article-title":"Sorafenib kills liver cancer cells by disrupting SCD1-mediated synthesis of monounsaturated fatty acids via the ATP\u2013AMPK\u2013mTOR\u2013SREBP1 signaling pathway","volume":"33","author":"Liu","year":"2019","journal-title":"FASEB J"},{"key":"10.1016\/j.apsb.2021.09.019_bib220","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/s41392-021-00594-4","article-title":"UBQLN1 mediates sorafenib resistance through regulating mitochondrial biogenesis and ROS homeostasis by targeting PGC1beta in hepatocellular carcinoma","volume":"6","author":"Xu","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.apsb.2021.09.019_bib221","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.cmet.2018.10.012","article-title":"Preclinical models for studying NASH-driven HCC: how useful are they?.","volume":"29","author":"Febbraio","year":"2019","journal-title":"Cell Metab"},{"key":"10.1016\/j.apsb.2021.09.019_bib222","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/s41575-019-0217-8","article-title":"Metabolic rearrangements in primary liver cancers: cause and consequences","volume":"16","author":"Satriano","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.apsb.2021.09.019_bib223","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/ncb2172","article-title":"p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase","volume":"13","author":"Jiang","year":"2011","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.apsb.2021.09.019_bib224","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/cr.2015.33","article-title":"cMyc-mediated activation of serine biosynthesis pathway is critical for cancer progression under nutrient deprivation conditions","volume":"25","author":"Sun","year":"2015","journal-title":"Cell Res"},{"key":"10.1016\/j.apsb.2021.09.019_bib225","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.celrep.2018.07.001","article-title":"Organoid models of human liver cancers derived from tumor needle biopsies","volume":"24","author":"Nuciforo","year":"2018","journal-title":"Cell Rep"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383521003610?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383521003610?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T16:51:53Z","timestamp":1761929513000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383521003610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":225,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S2211383521003610"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2021.09.019","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2021.09.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}